Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (331-340 of 539) with videos related to

Pageof 54
Sort By:
Haematologica|July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Blood|November 19, 2005
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow TransplantationStefan O Schönland, Henk Lokhorst, Agnes Buzyn, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
British Journal of Haematology|March 13, 2020
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group modelRoman Hájek, Viera Sandecka, Ivan Špička, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell TransplantationRoland Fenk, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemiaAthanasios Anagnostopoulos, Parameswaran N Hari, Waleska S Pérez, et al.
Leukemia|October 11, 2023
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disordersSebastian Köhrer, Tobias Dittrich, Martin Schorb, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantationMaximilian Merz, Lina Jansen, Felipe A Castro, et al.
Pageof 54

Showing results (331-340 of 539) with videos related to

Sort By:
Pageof 54
Haematologica|July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica|May 13, 2017
Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantationMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Nature Communications|April 27, 2018
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expressionMina Ali, Ram Ajore, Anna-Karin Wihlborg, et al.
Blood|November 19, 2005
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow TransplantationStefan O Schönland, Henk Lokhorst, Agnes Buzyn, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
British Journal of Haematology|March 13, 2020
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group modelRoman Hájek, Viera Sandecka, Ivan Špička, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell TransplantationRoland Fenk, Aristoteles Giagounidis, Hartmut Goldschmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemiaAthanasios Anagnostopoulos, Parameswaran N Hari, Waleska S Pérez, et al.
Leukemia|October 11, 2023
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disordersSebastian Köhrer, Tobias Dittrich, Martin Schorb, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantationMaximilian Merz, Lina Jansen, Felipe A Castro, et al.
Pageof 54